COMPARE · Reviewed July 29, 2026
EXEL vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. EXEL scored 72.6, HALO scored 81.3 — HALO leads.
Compare another set
EXEL
Exelixis, Inc.
72.6
$55.33 · $13.9B
fundamentals as of
Score gap
8.7
HALO leads
HALO
Halozyme Therapeutics, Inc.
81.3
$83.28 · $9.9B
fundamentals as of
The model, pillar by pillar (0–100 each)
EXEL
stronger →← stronger
HALO
96
Qualityreturns · margins · balance sheet
81
74
Growthrevenue & earnings expansion
100
54
Valuevaluation vs sector peers
66
HALO is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
EXEL
HALO
$918mC+
FCF
$668mC+
+3.3%C+
Rev
+39.1%A
0.09B+
D/E
9.91D
18.3xA-
P/E
29.2xB
2.56C
PEG
0.78A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
EXEL
HALO
20% below
Price vs fair valuelower is cheaper
43% below
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
~0%/yr
+8%
1-yr DCF upside
+37%
+25%
5-yr DCF upside
+76%
+55%
10-yr DCF upside
+158%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EXEL
Why this score
- Buying back stock
- Durable high returns
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
EXELExelixis, Inc.
Why now
Biotechnology · market cap $13.9b. 4% off the 52-week high of $57.57. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $52.07 (implying -6% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 110% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $9.9b. Trading near 52-week high of $84.44 — momentum setup, limited technical margin of safety. Revenue growing +39% — in hypergrowth territory. PEG 0.78 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $86.89 (implying +4% upside).
Moat
Net margin 23% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 191% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 9.91 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.